MBBS OSCE · Cardiology

OSCE — Prosthetic Valves and Anticoagulation

Eight-minute OSCE station on Prosthetic Valves and Anticoagulation: focused history, examination priorities, investigations, emergency and definitive management.

8 min stationVerification in progress
On this page
Study tools

Exam tags

NEET-PGINICETUSMLEPLAB

Brief (to candidate)

You will assess a patient with a presentation consistent with Prosthetic Valves and Anticoagulation.
You have 8 minutes to take a focused history, outline examination, investigations, and management including red flags.[1]

Clinical context

Prosthetic heart valves are mechanical (lifelong warfarin; ACC/AHA INR of 3.0 after mechanical mitral replacement, INR of 2.5 after bileaflet aortic replacement without thromboembolic risk factors) or bioprosthetic (no lifelong VKA for the valve itself; RIVER if AF). DOACs are contraindicated in mechanical valves (RE-ALIGN; PROACT-Xa stopped after 863 patients for excess thromboembolism). After TAVI without another indication, rivaroxaban caused harm (GALILEO). Acute valve thrombosis: TEE; inadequate anticoagulation in 82 percent; lysis complete success 86 percent in a TEE-guided series.[1][3][6][7][13][20]

Candidate tasks

  1. Clarify onset, severity, associated features, and red-flag symptoms.
  2. State focused examination priorities.
  3. List first-line investigations and any named score/criteria.
  4. Give immediate resuscitation steps.
  5. Outline definitive management with doses/routes where standard.
  6. Name complications and disposition (ward / HDU / theatre / discharge safety-net).
  7. Mention one special-population modifier (pregnancy, child, elderly, CKD).
[1]

Examiner checklist

DomainPass behaviours
DefinitionCorrect working diagnosis language
AssessmentFocused, prioritised, red flags sought
InvestigationsAppropriate first-line + interpretation
Emergency careABC / time-critical actions first
Definitive careSpecific drugs/procedures, not generic phrases
SafetyAcute prosthetic valve thrombosis — TEE; anticoagulation inadequate in 82%; lysis success 86%
SafetyMechanical mitral INR under 2.5 — thrombosis risk; TEE if symptomatic
SafetyDOAC in a mechanical valve — contraindicated (RE-ALIGN)
SafetyDabigatran (or any DOAC) in a mechanical valve — CONTRAINDICATED. RE-ALIGN trial
CommunicationClear plan and safety-netting

Model outline

Lead with the working diagnosis and life threats. Resuscitate before definitive tests when unstable. Use guideline-standard therapy with named agents and doses: ACC/AHA INR of 3.0 after a mechanical mitral prosthesis and after high-risk mechanical aortic replacement; INR of 2.5 after bileaflet aortic replacement without thromboembolic risk factors; never a DOAC in a mechanical valve. Document escalation criteria and follow-up (initial TTE, then 5 and 10 years, then annually). A safe candidate is specific, structured, and never delays critical care for non-urgent imaging.[1][3][13]

References20Show
  1. [1]Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation, 2021.PMID 33332150
  2. [2]Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease Eur Heart J, 2022.PMID 34453165
  3. [3]Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves N Engl J Med, 2013.PMID 23991661
  4. [4]Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J, 2017.PMID 29020344
  5. [5]Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis N Engl J Med, 2014.PMID 24678937
  6. [6]Guimarães HP, Lopes RD, de Barros E Silva PGM, et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve N Engl J Med, 2020.PMID 33196155
  7. [7]Dangas GD, Tijssen JGP, Wöhrle J, et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement N Engl J Med, 2020.PMID 31733180
  8. [8]Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM) Eur Heart J, 2015.PMID 26320109
  9. [9]Jawitz OK, Wang TY, Lopes RD, et al. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve Am Heart J, 2020.PMID 32693197
  10. [10]Puskas JD, Gerdisch M, Nichols D, et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial J Thorac Cardiovasc Surg, 2014.PMID 24512654
  11. [11]Chu MWA, Ruel M, Graeve A, et al. Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Trial Ann Thorac Surg, 2023.PMID 36610532
  12. [12]Kovacs MJ, Wells PS, Anderson DR, et al. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial BMJ, 2021.PMID 34108229
  13. [13]Lengyel M, Vandor L The role of thrombolysis in the management of left-sided prosthetic valve thrombosis: a study of 85 cases diagnosed by transesophageal echocardiography J Heart Valve Dis, 2001.PMID 11603604
  14. [14]van der Zande JA, Ramlakhan KP, Sliwa K, et al. Pregnancy with a prosthetic heart valve, thrombosis, and bleeding: the ESC EORP Registry of Pregnancy and Cardiac disease III Eur Heart J, 2026.PMID 40237423
  15. [15]Ostermann H, von Heymann C Prothrombin complex concentrate for vitamin K antagonist reversal in acute bleeding settings: efficacy and safety Expert Rev Hematol, 2019.PMID 31159607
  16. [16]Jeong SI, Kim HR, Song JY, et al. Inappropriate antibiotic prophylaxis before dental procedures in congenital heart disease: Insights from a nationwide Korean cohort J Infect Public Health, 2026.PMID 41270450
  17. [17]Pradhan A, Mahalawat S, Perrone MA From the INVICTUS Trial to Current Considerations: It's Not Time to Retire Vitamin K Inhibitors Yet! Pharmaceuticals (Basel), 2024.PMID 39598370
  18. [18]Habets J, Tanis W, Reitsma JB, et al. Are novel non-invasive imaging techniques needed in patients with suspected prosthetic heart valve endocarditis? A systematic review and meta-analysis. Eur Radiol, 2015.PMID 25680715
  19. [19]Lengyel M Management of prosthetic valve thrombosis. J Heart Valve Dis, 2004.PMID 15222276
  20. [20]Wang TY, Svensson LG, Wen J, et al. Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve NEJM Evid, 2023.PMID 38320162
OSCE — Prosthetic Valves and Anticoagulation · MBBS OSCE · NeetVellum